European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
-
Eur. J. Paediatr. Neurol. · May 2014
Case ReportsHemiconvulsion-Hemiplegia-Epilepsy syndrome associated with inflammatory-degenerative hystopathological findings in child with congenital adrenal hyperplasia.
Hemiconvulsion-Hemiplegia (HH) syndrome represents an uncommon consequence of prolonged unilateral clonic or hemiconvulsive status epilepticus in childhood, usually occurring during a febrile illness, followed by ipsilateral hemiplegia. The subsequent appearance of focal seizures configures the so called Hemiconvulsion-Hemiplegia-Epilepsy (HHE) syndrome. The pathogenesis of HH/HHE syndrome is still unclear. ⋯ Disregulation of the inflammatory cascade has been proposed as one of the possible pathogenetic mechanisms underlying HH/HHE syndrome. To our knowledge however, this is the first report of an association with a histologically documented inflammatory process. The clinical and histopathological findings of our reported case lend support to the possible role of inflammation in the pathogenesis of HH/HHE syndrome.
-
Eur. J. Paediatr. Neurol. · May 2014
Outcomes of hypoxic ischaemic encephalopathy treated with therapeutic hypothermia using cool gel packs - experience from Western Australia.
Therapeutic hypothermia is the standard clinical practice for neonates with moderate to severe hypoxic ischaemic encephalopathy (HIE). ⋯ Neonates undergoing therapeutic hypothermia with cool gel packs had both good survival rates and long term neurodevelopmental outcomes and met international benchmarks.
-
Eur. J. Paediatr. Neurol. · Mar 2014
Onabotulinumtoxin A injections: a safety review of children with clubfoot under 2 years of age at BC Children's Hospital.
Pediatric indications for Onabotulinumtoxin A extend beyond treatment of skeletal muscle conditions. Each of the indications for Onabotulinumtoxin A use have adverse events reported in the past. The aim of this study was to review dverse events in children less than 2 years of age who were treated with Onabotulinumtoxin A injections as part of equinus foot deformity, in the setting of clubfoot at British Columbia's Children Hospital. ⋯ Onabotulinumtoxin A appears to be safe with respect to the adverse events, for use in children under 2 years of age with the diagnosis of clubfoot when dosed at 10 units per kilogram. However, the dose of Onabotulinumtoxin A and underlying diagnosis should always be kept in mind.
-
Eur. J. Paediatr. Neurol. · Jan 2014
Multicenter StudyEfficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.
Lacosamide is effective and well-tolerated antiepileptic drug (AED) in both children and adults. ⋯ We conclude that lacosamide is an effective and a well-tolerated antiepileptic drug in an etiologically wide range of focal seizures. Therefore, lacosamide might represent a possible therapeutic option in infants and young children affected by uncontrolled focal epilepsy.
-
Eur. J. Paediatr. Neurol. · Jan 2014
Continuation rates of levetiracetam in children from the EULEVp cohort study.
Since indication extension to children data regarding the effectiveness of levetiracetam in paediatric patients remains limited. ⋯ In real-life clinical practice important treatment retention and non-negligible reduction of seizure frequency may be expected.